An international clinical trial for myelofibrosis patients is currently in phase 3 and is actively enrolling in almost 150 sites across the world.
The MPN AA has been asked to raise awareness because there are trial sites in Australia (see below).  If you have myelofibrosis and think it might be relevant for you, you would need to ask your haematologist.

We understand that this phase 3 trial may be suitable for MPN adults patients with myelofibrosis who have not been treated with JAK inhibitor, have a platelet count >100 × 109/L, and with active symptoms.

The trial is studying selinexor in combination with ruxolitinib versus ruxolitinib plus placebo in patients with myelofibrosis.

This trial’s international identification is NCT04562389.  The clinical trial is titled XPORT-MF-034 (SENTRY), and is in phase 3.

The following Australian trial sites are either active or planned for activation:

LOCATION	HAEMATOLOGIST CONTACT
QLD: Icon Cancer Centre – Wesley	Dr Ian Irving
NSW: Liverpool Hospital	Dr Bartlomiej Getta
NSW: Campbelltown Hospital	Dr Bartlomiej Getta
NSW: Bankstown-Lidcombe Hospital	Dr Bartlomiej Getta
SA: Royal Adelaide Hospital	Dr David Ross

For further information about the SENTRY trial and whether this is something that might be suitable for you, you would need to speak to your haematologist.

Please note that the MPN AA is a volunteer patient group. We are not experts and therefore not in a position to endorse any clinical trial. You need to make your own inquiries together with your medical team.

For further information about clinical trials see the Australian and New Zealand Clinical Trials Registry information for Participants or the Leukaemia Foundation Clinical Trials page.